Johnson Investment Counsel Inc. Has $2.04 Million Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Johnson Investment Counsel Inc. cut its holdings in Repligen Co. (NASDAQ:RGEN) by 6.8% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 14,146 shares of the biotechnology company’s stock after selling 1,035 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Repligen were worth $2,036,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Resources Management Corp CT ADV acquired a new stake in shares of Repligen in the third quarter valued at $37,000. Quarry LP increased its stake in shares of Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 239 shares in the last quarter. UMB Bank n.a. increased its stake in shares of Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 110 shares in the last quarter. Global Retirement Partners LLC increased its stake in shares of Repligen by 54.0% in the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 129 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in shares of Repligen by 15.2% in the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 90 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Stock Up 7.4 %

Shares of Repligen stock opened at $147.13 on Wednesday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $200.23. The business has a fifty day simple moving average of $157.16 and a 200 day simple moving average of $148.52. The stock has a market cap of $8.24 billion, a PE ratio of -288.49, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Research analysts predict that Repligen Co. will post 1.72 EPS for the current year.

Wall Street Analysts Forecast Growth

RGEN has been the subject of a number of recent research reports. HC Wainwright restated a “buy” rating and set a $180.00 target price on shares of Repligen in a research report on Friday, February 21st. TD Cowen initiated coverage on Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 target price for the company. Canaccord Genuity Group boosted their target price on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. Wolfe Research initiated coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, Canaccord Genuity Group initiated coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Repligen has a consensus rating of “Moderate Buy” and an average price target of $181.00.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.